2024年12月24日 · DECR2 (2,4-Dienoyl-CoA Reductase 2) is a Protein Coding gene. Diseases associated with DECR2 include Acute Inflammation Of Lacrimal Passage and Dacryocystitis. Among its related pathways are Peroxisomal lipid metabolism and Metabolism.

2024年1月12日 · DECR2 is upregulated in clinical PCa, most notably in metastatic castrate-resistant PCa (CRPC). Depletion of DECR2 significantly suppressed proliferation, migration, and 3D growth of a range of...

Auxiliary enzyme of beta-oxidation. Participates in the degradation of unsaturated fatty enoyl-CoA esters having double bonds in both even- and odd-numbered positions in peroxisome. Catalyzes the NADP-dependent reduction of 2,4-dienoyl-CoA to yield trans-3-enoyl-CoA.

2020年5月19日 · Among the top candidates, 2,4-dienoyl-CoA reductase (DECR1), a mitochondrial enzyme involved in polyunsaturated fatty acid (PUFA) degradation, represents a potential...

鉴定了编码过氧化物酶体 2,4-二烯酰辅酶 A 还原酶 Decr2 的基因。 为了研究 Decr2 在体内肿瘤生长和免疫反应中的作用，将 Decr2 敲低或 Decr2 过表达的肿瘤移植到 C57BL/6 小鼠中，用于研究抗 PD-L1 功效和免疫反应分析。

DECR2 influences cell cycle progression and lipid metabolism to support tumour cell proliferation. Further, co-targeting of perFAO and standard-of-care androgen receptor inhibition enhanced ...

在此，我们探讨了靶向 perFAO 在 PCa 细胞和临床前列腺肿瘤中的治疗效果，随后将过氧化物酶体 2,4-二烯酰辅酶 A 还原酶 2 (DECR2) 确定为关键治疗靶点。DECR2 在临床 PCa 中显着上调，尤其是在转移性去势抵抗性 PCa 中。DECR2 的消耗显着抑制了增殖、迁移、在体内。

Depletion of DECR2 significantly suppressed proliferation, migration, and 3D growth of a range of CRPC and therapy-resistant PCa cell lines, and inhibited LNCaP tumour growth and proliferation in vivo. DECR2 influences cell cycle progression and lipid metabolism to …

Enables 2,4-dienoyl-CoA reductase (NADPH) activity and trans-2-enoyl-CoA reductase (NADPH) activity. Involved in unsaturated fatty acid biosynthetic process. Predicted to be located in peroxisome. [provided by Alliance of Genome Resources, Apr 2022] 生物活性分子 (1)

2022年11月5日 · Herein, we explored the therapeutic efficacy of targeting perFAO in PCa cells and clinical prostate tumours, and subsequently identified peroxisomal 2,4-dienoyl CoA reductase 2 (DECR2), as a key therapeutic target. DECR2 is markedly upregulated in clinical PCa, most notably in metastatic castrate-resistant PCa.